"
Team:Penn/Targeting
From 2012.igem.org
(Difference between revisions)
| Line 1: | Line 1: | ||
{{:Team:Penn/Template/Site}} | {{:Team:Penn/Template/Site}} | ||
<html> | <html> | ||
| + | <style type="text/css"> | ||
| + | .fig{font-size:11px; width:500px; margin:10px auto;} | ||
| + | </style> | ||
| + | <div style="background-color:White;padding:20px 60px 20px 60px; text-align:justify;"> | ||
| - | < | + | <h1 align="center"><b>Testing the Displayed HER2 Darpin on Cancer Cells</b></h1><br /> |
| - | |||
<p style="color:black;text-indent:30px;"> | <p style="color:black;text-indent:30px;"> | ||
| Line 14: | Line 17: | ||
To verify that our SKBR3 cells overexpressed HER2, we immunostained for HER2 (primary anti-Neu Mouse Igg, Santa Cruz Biotechnology and secondary donkey anti-mouse Alexa-Fluor 647 conjugate, Jackson Immunoresearch) and visualized the cells on a confocal microscope. As expected, HER2 was overexpressed in SKBR3 cells (Figure 10).</p> | To verify that our SKBR3 cells overexpressed HER2, we immunostained for HER2 (primary anti-Neu Mouse Igg, Santa Cruz Biotechnology and secondary donkey anti-mouse Alexa-Fluor 647 conjugate, Jackson Immunoresearch) and visualized the cells on a confocal microscope. As expected, HER2 was overexpressed in SKBR3 cells (Figure 10).</p> | ||
| - | + | <div class="fig"><div align="center"><img src="https://static.igem.org/mediawiki/2012/e/e0/SKBR3_%28%2BDAPI%29_%28%2BAB1%29_%28%2BAB2%29_630x.jpg " width="250" height="250"><br> | |
| - | <img src="https://static.igem.org/mediawiki/2012/e/e0/SKBR3_%28%2BDAPI%29_%28%2BAB1%29_%28%2BAB2%29_630x.jpg " width="250" height="250" | + | <b>Figure 10</b></div>Figure 10: SKBR3 cells over-express HER2 on their surface. Red indicates HER2 (Alexa-Fluor 647), Blue indicates DAPI.</div> |
| - | < | + | |
<p style="color:black;text-indent:30px;">To assay whether our DARPin-displaying E. coli bound to SKBR3 cells preferentially, we conducted experiments in which our bacteria were co-incubated with SKBR3 or HEK293T cells. The DARPin-displaying bacteria were co-transformed with eGFP for easy visualization. These experiments are still in progress to optimize the co-incubation and gentamycin protection protocol (we designed this type of experiment ourselves since it has not been done before). However, preliminary results are exciting and show preferential binding to SKBR3 cells (Figures 11 and 12).</p> | <p style="color:black;text-indent:30px;">To assay whether our DARPin-displaying E. coli bound to SKBR3 cells preferentially, we conducted experiments in which our bacteria were co-incubated with SKBR3 or HEK293T cells. The DARPin-displaying bacteria were co-transformed with eGFP for easy visualization. These experiments are still in progress to optimize the co-incubation and gentamycin protection protocol (we designed this type of experiment ourselves since it has not been done before). However, preliminary results are exciting and show preferential binding to SKBR3 cells (Figures 11 and 12).</p> | ||
| - | <img src="https://static.igem.org/mediawiki/2012/a/ad/HEK%27s.jpg " width="250" height="250" | + | <div class="fig"><div align="center"><img src="https://static.igem.org/mediawiki/2012/a/ad/HEK%27s.jpg " width="250" height="250"><br> |
| - | < | + | <b>Figure 11</b></div>Figure 11: HEK293T cells do not express a large amount of HER2, and DARPin-displaying bacteria do not preferentially bind to them. Red indicates HER2 (Alexa-Fluor 647), Blue indicates DAPI. Green indicates eGFP. Bacteria were co-incubated at a Multiplicity of Infection of 200:1 and washed three times after co-incubation.</div> |
| - | + | <div class="fig"><div align="center"><img src="https://static.igem.org/mediawiki/2012/c/c8/IMG_3309.JPG" width="250" height="250"><br> | |
| - | <img src="https://static.igem.org/mediawiki/2012/c/c8/IMG_3309.JPG" width="250" height="250" | + | <b>Figure 12</b></div>Figure 12: SKBR3 cells overexpress HER2 and DARPin-displaying bacteria bind to their surface. Red indicates HER2 (Alexa-Fluor 647), Blue indicates DAPI. Green indicates eGFP. Bacteria were co-incubated at a Multiplicity of Infection of 200:1 and washed three times after co-incubation.</div> |
| - | < | + | |
| - | + | ||
In summary, we demonstrated surface display of DARPin H10-2-G3 for the first time and have preliminary evidence showing our DARPin-displaying bacteria can target cancer cells. We also developed a generalized surface display BioBrick for any iGEM team to use. | In summary, we demonstrated surface display of DARPin H10-2-G3 for the first time and have preliminary evidence showing our DARPin-displaying bacteria can target cancer cells. We also developed a generalized surface display BioBrick for any iGEM team to use. | ||
Revision as of 14:31, 22 October 2012
Testing the Displayed HER2 Darpin on Cancer Cells
After verifying that the DARPin was displayed on the cell surface, we sought to test whether it could allow binding to HER2-overexpressing cancer cells. We were generously provided SKBR3 cells by the lab of Matthew Lazzara. These cells are derived from breast cancer cells and over-express HER2. We also obtained Human Embryonic Kidney (HEK) 293T cells, which express a low amount of HER2, to act as controls.
To verify that our SKBR3 cells overexpressed HER2, we immunostained for HER2 (primary anti-Neu Mouse Igg, Santa Cruz Biotechnology and secondary donkey anti-mouse Alexa-Fluor 647 conjugate, Jackson Immunoresearch) and visualized the cells on a confocal microscope. As expected, HER2 was overexpressed in SKBR3 cells (Figure 10).
Figure 10
To assay whether our DARPin-displaying E. coli bound to SKBR3 cells preferentially, we conducted experiments in which our bacteria were co-incubated with SKBR3 or HEK293T cells. The DARPin-displaying bacteria were co-transformed with eGFP for easy visualization. These experiments are still in progress to optimize the co-incubation and gentamycin protection protocol (we designed this type of experiment ourselves since it has not been done before). However, preliminary results are exciting and show preferential binding to SKBR3 cells (Figures 11 and 12).
Figure 11
Figure 12
